Alnylam Pharmaceuticals Stock Net Asset

ALNY Stock  USD 250.00  6.45  2.52%   
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
Other Current LiabTotal Assets
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Alnylam Pharmaceuticals Company Net Asset Analysis

Alnylam Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current Alnylam Pharmaceuticals Net Asset

    
  4.24 B  
Most of Alnylam Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Alnylam Net Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Net Asset. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
-0.150.39-0.980.890.970.930.990.960.260.880.330.850.890.83-0.250.99-0.63-0.60.82-0.85-0.890.570.94
-0.15-0.630.29-0.15-0.15-0.49-0.13-0.190.33-0.550.18-0.39-0.50.190.99-0.08-0.450.14-0.63-0.10.39-0.61-0.46
0.39-0.63-0.520.320.480.570.350.460.090.580.230.470.480.29-0.590.360.09-0.420.52-0.35-0.630.450.54
-0.980.29-0.52-0.91-0.96-0.96-0.96-0.98-0.18-0.94-0.36-0.89-0.92-0.810.38-0.970.550.64-0.880.850.95-0.58-0.96
0.89-0.150.32-0.910.870.840.880.920.10.840.320.760.80.78-0.250.93-0.6-0.510.77-0.79-0.850.420.84
0.97-0.150.48-0.960.870.910.950.970.30.850.350.840.860.8-0.240.97-0.55-0.710.78-0.91-0.870.540.91
0.93-0.490.57-0.960.840.910.920.910.110.970.220.890.960.66-0.580.89-0.39-0.580.95-0.72-0.930.720.99
0.99-0.130.35-0.960.880.950.920.930.190.890.290.850.90.82-0.240.97-0.66-0.560.84-0.83-0.860.60.92
0.96-0.190.46-0.980.920.970.910.930.30.860.460.870.850.8-0.280.98-0.53-0.720.8-0.91-0.930.440.93
0.260.330.09-0.180.10.30.110.190.3-0.040.620.01-0.060.380.330.25-0.21-0.27-0.11-0.32-0.12-0.030.19
0.88-0.550.58-0.940.840.850.970.890.86-0.040.210.870.960.62-0.630.85-0.36-0.510.98-0.65-0.90.750.96
0.330.180.23-0.360.320.350.220.290.460.620.210.270.130.430.160.4-0.27-0.440.13-0.49-0.37-0.130.32
0.85-0.390.47-0.890.760.840.890.850.870.010.870.270.940.57-0.490.85-0.37-0.590.87-0.71-0.860.490.91
0.89-0.50.48-0.920.80.860.960.90.85-0.060.960.130.940.57-0.60.85-0.38-0.50.97-0.65-0.850.720.95
0.830.190.29-0.810.780.80.660.820.80.380.620.430.570.570.110.85-0.81-0.470.51-0.81-0.730.310.66
-0.250.99-0.590.38-0.25-0.24-0.58-0.24-0.280.33-0.630.16-0.49-0.60.11-0.18-0.350.17-0.71-0.020.46-0.65-0.55
0.99-0.080.36-0.970.930.970.890.970.980.250.850.40.850.850.85-0.18-0.64-0.650.78-0.9-0.90.450.91
-0.63-0.450.090.55-0.6-0.55-0.39-0.66-0.53-0.21-0.36-0.27-0.37-0.38-0.81-0.35-0.640.12-0.280.560.42-0.12-0.38
-0.60.14-0.420.64-0.51-0.71-0.58-0.56-0.72-0.27-0.51-0.44-0.59-0.5-0.470.17-0.650.12-0.450.850.68-0.15-0.6
0.82-0.630.52-0.880.770.780.950.840.8-0.110.980.130.870.970.51-0.710.78-0.28-0.45-0.55-0.840.780.94
-0.85-0.1-0.350.85-0.79-0.91-0.72-0.83-0.91-0.32-0.65-0.49-0.71-0.65-0.81-0.02-0.90.560.85-0.550.81-0.21-0.73
-0.890.39-0.630.95-0.85-0.87-0.93-0.86-0.93-0.12-0.9-0.37-0.86-0.85-0.730.46-0.90.420.68-0.840.81-0.46-0.92
0.57-0.610.45-0.580.420.540.720.60.44-0.030.75-0.130.490.720.31-0.650.45-0.12-0.150.78-0.21-0.460.69
0.94-0.460.54-0.960.840.910.990.920.930.190.960.320.910.950.66-0.550.91-0.38-0.60.94-0.73-0.920.69
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Alnylam Total Assets

Total Assets

4.45 Billion

At this time, Alnylam Pharmaceuticals' Total Assets are fairly stable compared to the past year.
Based on the recorded statements, Alnylam Pharmaceuticals has a Net Asset of 4.24 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.

Alnylam Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.
4.2B7.2B6.8B5.4B100%
Alnylam Pharmaceuticals is currently under evaluation in net asset category among its peers.

Alnylam Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.
61.1%
Environmental
62.4%
Governance
Social

Alnylam Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Alnylam Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alnylam Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alnylam Pharmaceuticals' value.
Shares
T. Rowe Price Associates, Inc.2024-09-30
3.5 M
T. Rowe Price Investment Management,inc.2024-09-30
3.1 M
Norges Bank2024-12-31
2.5 M
Geode Capital Management, Llc2024-09-30
2.1 M
American Century Companies Inc2024-12-31
1.6 M
Groupama Asset Management2024-09-30
1.5 M
Capital Research & Mgmt Co - Division 32024-12-31
1.4 M
Orbis Allan Gray Ltd2024-09-30
1.3 M
Winslow Capital Management, Llc2024-09-30
961.6 K
Capital World Investors2024-12-31
16.6 M
Fmr Inc2024-09-30
14.7 M

Alnylam Fundamentals

Return On Equity-15.01
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-600%-400%-200%0%200%400%600%800%
Return On Asset-0.0274
Profit Margin(0.12) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Operating Margin(0.18) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Current Valuation31.8 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110%20%30%40%
Shares Outstanding129.46 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%30,000%35,000%
Shares Owned By Insiders4.08 %
Shares Owned By Institutions96.89 %
Number Of Shares Shorted2.94 M
Price To Earning(22.92) X
Price To Book494.86 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100,000%-50,000%0%50,000%
Price To Sales14.40 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%500%
Revenue2.25 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200,000%400,000%600,000%800,000%1,000,000%1,200,000%1,400,000%
Gross Profit1.92 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200,000%400,000%600,000%800,000%1,000,000%1,200,000%
EBITDA(178.85 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%20,000%
Net Income(278.16 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%
Cash And Equivalents2.27 B
Cash Per Share18.41 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Total Debt1.3 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000%40,000%60,000%80,000%100,000%120,000%140,000%
Debt To Equity5.63 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-30,000%-20,000%-10,000%0%10,000%
Current Ratio3.48 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Book Value Per Share0.52 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%-150%-100%-50%
Cash Flow From Operations(8.31 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%10,000%20,000%30,000%40,000%50,000%
Short Ratio4.37 X
Earnings Per Share(2.18) X
Price To Earnings To Growth(0.49) X
Target Price301.27
Number Of Employees2.23 K
Beta0.35
Market Capitalization32.36 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%
Total Asset4.24 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%
Retained Earnings(7.29 B)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150,000%100,000%150,000%
Working Capital2.11 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset1.11 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%
Current Liabilities62.1 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%
Net Asset4.24 B

About Alnylam Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.


 
News Freq…Investor S…